Atorvastatin Cuts Cardiovascular Events But Fails Disability Goal
Atorvastatin reduced major cardiovascular events by 30 percent in older adults without known cardiovascular disease, diabetes, or dementia, according to findings presented at the ESC Congress 2026 and published in the New England Journal of Medicine. Led by researchers at Monash University, the STAREE trial evaluated 9,971 participants aged 70 and older over a median … Read more